Fortress Biotech Stock Current Asset
| FBIO Stock | USD 1.70 0.02 1.16% |
Fortress Biotech fundamentals help investors to digest information that contributes to Fortress Biotech's financial success or failures. It also enables traders to predict the movement of Fortress Stock. The fundamental analysis module provides a way to measure Fortress Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Fortress Biotech stock.
At this time, Fortress Biotech's Other Current Assets are very stable compared to the past year. As of the 21st of March 2025, Total Current Assets is likely to grow to about 156.5 M, while Non Current Assets Total are likely to drop about 45.3 M. Fortress | Current Asset |
Fortress Biotech Company Current Asset Analysis
Fortress Biotech's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Fortress Biotech Current Asset | 99.94 M |
Most of Fortress Biotech's fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Fortress Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Fortress Current Asset Historical Pattern
Today, most investors in Fortress Biotech Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Fortress Biotech's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Fortress Biotech current asset as a starting point in their analysis.
Fortress Biotech Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Fortress Total Assets
Total Assets |
|
In accordance with the recently published financial statements, Fortress Biotech has a Current Asset of 99.94 M. This is 95.36% lower than that of the Biotechnology sector and 90.58% lower than that of the Health Care industry. The current asset for all United States stocks is 98.93% higher than that of the company.
Fortress Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Fortress Biotech's direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Fortress Biotech could also be used in its relative valuation, which is a method of valuing Fortress Biotech by comparing valuation metrics of similar companies.Fortress Biotech is currently under evaluation in current asset category among its peers.
Fortress Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Fortress Biotech from analyzing Fortress Biotech's financial statements. These drivers represent accounts that assess Fortress Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Fortress Biotech's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 228.3M | 204.3M | 58.7M | 24.4M | 22.0M | 20.9M | |
| Enterprise Value | 84.0M | (26.5M) | 7.7M | 32.1M | 36.9M | 53.6M |
Fortress Fundamentals
| Return On Equity | -17.4 | ||||
| Return On Asset | -0.38 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (1.51) % | ||||
| Current Valuation | 60.16 M | ||||
| Shares Outstanding | 27.6 M | ||||
| Shares Owned By Insiders | 27.70 % | ||||
| Shares Owned By Institutions | 17.30 % | ||||
| Number Of Shares Shorted | 3.69 M | ||||
| Price To Earning | (2.92) X | ||||
| Price To Book | 2.24 X | ||||
| Price To Sales | 0.58 X | ||||
| Revenue | 84.51 M | ||||
| Gross Profit | (4.17 M) | ||||
| EBITDA | (133.64 M) | ||||
| Net Income | (60.64 M) | ||||
| Cash And Equivalents | 208.35 M | ||||
| Cash Per Share | 1.92 X | ||||
| Total Debt | 88.59 M | ||||
| Debt To Equity | 1.24 % | ||||
| Current Ratio | 2.43 X | ||||
| Book Value Per Share | 0.77 X | ||||
| Cash Flow From Operations | (128.22 M) | ||||
| Short Ratio | 13.38 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 15.33 | ||||
| Number Of Employees | 186 | ||||
| Beta | 1.75 | ||||
| Market Capitalization | 47.48 M | ||||
| Total Asset | 167.53 M | ||||
| Retained Earnings | (694.87 M) | ||||
| Working Capital | 32.11 M | ||||
| Current Asset | 99.94 M | ||||
| Current Liabilities | 10.58 M | ||||
| Net Asset | 167.53 M |
About Fortress Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Fortress Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fortress Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fortress Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Fortress Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fortress Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fortress Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Fortress Stock
Moving against Fortress Stock
| 0.71 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.7 | FNA | Paragon 28 | PairCorr |
| 0.54 | CMRX | Chimerix Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Fortress Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fortress Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fortress Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fortress Biotech to buy it.
The correlation of Fortress Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fortress Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fortress Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fortress Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Fortress Biotech Piotroski F Score and Fortress Biotech Altman Z Score analysis. To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth (0.07) | Return On Assets | Return On Equity |
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.